Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma.

@article{Kim1999PhaseIC,
  title={Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma.},
  author={N K Kim and Seock Ah Im and Dong Wook Kim and Min Hyuk Lee and Chul Won Jung and Euk Kyung Cho and Jong Tae Lee and Jin Seok Ahn and Dae Seog DS Heo and Y. J. Bang},
  journal={Cancer},
  year={1999},
  volume={86 7},
  pages={1109-15}
}
BACKGROUND SKI-2053R (SK Chemicals, Kyungki-Do, South Korea) is a new platinum derivative with antitumor activity against various cell lines, including cisplatin-resistant tumor cell lines. Preclinical studies have suggested that it is less nephrotoxic than cisplatin. This study evaluated the efficacy and toxicity of SKI-2053R in the treatment of patients with advanced gastric adenocarcinoma. METHODS Thirty-seven patients with advanced gastric adenocarcinoma that was unresectable or… CONTINUE READING